Blueshift Asset Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Blueshift Asset Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,213	Closed	-$475K	–	667
2025 Q3	$475K	Buy	+1,213	New	+$507K	0.15%	209
2025 Q1	–	Sell	-1,729	Closed	-$696K	–	564
2024 Q4	$696K	Buy	+1,729	New	+$801K	0.25%	103
2023 Q1	–	Sell	-1,263	Closed	-$365K	–	464
2022 Q4	$365K	Buy	+1,263	New	+$385K	0.17%	177
2021 Q4	–	Sell	-9,671	Closed	-$1.75M	–	1246
2021 Q3	$1.75M	Buy	9,671 +3,749	+63%	+$732K	0.1%	271
2021 Q2	$1.19M	Buy	5,922 +1,924	+48%	+$402K	0.07%	312
2021 Q1	$859K	Buy	+3,998	New	+$878K	0.09%	311
2019 Q4	–	Sell	-2,964	Closed	-$502K	–	1056
2019 Q3	$502K	Buy	+2,964	New	+$524K	0.08%	373

Other funds holding VRTX

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Blueshift Asset Management's VRTX Position: Q4 2025 in Review

Blueshift Asset Management sold out of Vertex Pharmaceuticals (VRTX) in Q4 2025, closing a stake of 1,213 shares — an estimated $475K sold.

Blueshift Asset Management first reported a position in VRTX in Q3 2019 and held it in 7 quarters. The position peaked at $1.75M in Q3 2021. 1,670 funds tracked by Wall St. Rank hold VRTX as of Q4 2025.

Blueshift Asset Management reported no remaining Vertex Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Blueshift Asset Management sold 1,213 Vertex Pharmaceuticals shares in Q4 2025, an estimated $475K.
Blueshift Asset Management first reported a position in Vertex Pharmaceuticals in Q3 2019 and held it in 7 quarters.
Blueshift Asset Management's Vertex Pharmaceuticals position peaked at $1.75M in Q3 2021.
1,670 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2025.

Based on Blueshift Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.